Drug Profile
Aprutumab - Bayer
Alternative Names: BAY-1179470; FGFR-moAb; FGFR2-TTCLatest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Bayer
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Singapore (IV, Infusion)
- 28 Jan 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in South Korea (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Japan (IV, Infusion)